Latest InsightsIssuesImpressionsStories 

a blue ribbon symbol for prostate cancer beside a syringe on white surface

Eli Lilly signs cancer research deal with Stipple Bio worth up to $5.9 billion

The agreement covers multiple targets and drug types, with the upfront payment and the cancers involved undisclosed.

Eli Lilly has signed a research and licensing deal with Stipple Bio, a cancer-focused start-up, worth up to $5.9 billion including milestone payments, according to Fierce Biotech and Reuters as cited by RAPS. Lilly will make an upfront payment and an equity investment in Stipple, but the amounts were not disclosed. The deal also includes milestones tied to research, development and commercialisation, plus tiered royalties, which Fierce said are not itemised.

The collaboration covers multiple targets and multiple drug modalities, none of which was named. The cancers they will address have yet to be determined. Stipple’s own pipeline is aimed at solid tumours, including pancreatic cancer, and features antibody-drug conjugates, which deliver a toxic payload to cancer cells, and T-cell engagers, which direct immune cells to tumours.

Stipple’s approach centres on a platform called Pointillist, which it says discovers markers on the surface of cancer cells that are specific to cancer cells. The aim is to build medicines that avoid on-target, off-tumour toxicity, meaning damage to healthy tissue that carries the same target. Its lead candidate is STP-100. The company raised a $100 million Series A round in April, according to Fierce.

Headline figures for such agreements describe the maximum possible value, and most of that amount typically depends on milestones that are reached only if drugs succeed in development, which many do not. The Stipple announcement does not say how much Lilly has paid up front. Fierce reported that Lilly also struck a deal on the same Monday to acquire Calytrix Bio, and the details of that transaction were not available in the reports reviewed.

The announcements reviewed carry no direct quotes from either company, and GyanMuse has not seen the agreement itself. The deal terms are as reported by trade outlets. This article is for information only and is not investment or medical advice.

CATEGORIES:

Business-Health

Tags:

No responses yet

Leave a Reply